Table 1
From: Cardiovascular effects of the soluble guanylyl cyclase activator BAY 58–2667 in anesthetized dogs
-BAY 58–2667 low infusion rates | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BAY 58–2667 μg/kg/h | Time min | HR Δ % | BPS Δ % | BPD Δ % | BPM Δ % | LVP Δ % | LVEDP Δ % | LVdP/dt Δ % | CVP Δ % | CO Δ % | TPR Δ % | C58–2667 μg/L |
1 | 60 | 2 | -2 | -2 | -2 | 0 | -8 | -3 | -2 | -6 | 3 | 0.9 |
5 | 120 | 4 | -14 | -4 | -10 | -7 | -40 | -1 | -24 | -3 | -5 | 3.4 |
25 | 180 | 34 | -26 | -2 | -14 | -9 | -67 | 21 | -43 | 27 | -23 | 17.8 |
washout | 300 | 19 | -22 | 2 | -11 | -11 | -22 | 1 | -9 | 10 | -18 | 0.2 |
-BAY 58–2667 high infusion ratesa | ||||||||||||
BAY 58–2667 μg/kg/h | Time min | HR Δ % | BPS Δ % | BPD Δ % | BPM Δ % | LVP Δ % | LVEDP Δ % | LVdP/dt Δ % | CVP Δ % | CO Δ % | TPR Δ % | C58–2667 μg/L |
5 | 60 | 32 | -14 | -4 | -9 | -8 | -24 | 16 | -24 | 13 | -18 | 2.9 |
15 | 120 | 56 | -34 | -16 | -26 | -18 | -65 | 9 | -37 | 36 | -39 | 8.8 |
45 | 180 | 113 | -47 | -21 | -31 | -18 | -98 | 17 | -54 | 73 | -48 | 25.2 |
washout | 300 | 34 | -31 | -7 | -20 | -20 | -39 | -19 | -27 | 15 | -29 | 0.3 |